NCT07145229View on ClinicalTrials.gov

Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare

PHASE2RecruitingINTERVENTIONAL
Enrollment

380

Participants

Timeline

Start Date

August 26, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

June 30, 2026

Conditions
Acute Gouty ArthritisGout FlareGout FlaresAcute Gout Flare
Interventions
DRUG

ABP-745 Dose A

ABP-745 Dose A + Colchicine placebo - tablets (PO)

DRUG

ABP-745 Dose B

ABP-745 Dose B + Colchicine placebo - tablets (PO)

DRUG

Colchicine

ABP-745 placebo + Colchicine - tablets (PO)

DRUG

Placebo

ABP-745 placebo + Colchicine placebo - tablets (PO)

Trial Locations (5)

39501

RECRUITING

Gulfport Memorial, Gulfport

70115

RECRUITING

Touro Medical Center, New Orleans

70769

RECRUITING

Neighborhood Health, Prairieville

71303

RECRUITING

Northshore, Alexandria

74133

RECRUITING

Grassroots Healthcare, Tulsa

Sponsors
All Listed Sponsors
lead

Atom Therapeutics Co., Ltd

INDUSTRY

NCT07145229 - Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare | Biotech Hunter | Biotech Hunter